

⁵EMD Serono Research & Development Institute Inc., Billerica, United States

⁶Merck KGaA, Darmstadt, Germany

Integrated analysis of pooled clinical safety data allows comprehensive characterisation of the safety profile of cladribine tablets (CT) 10mg (3.5mg/kg cumulative dose over 2 years [CT3.5]) in patients with relapsing multiple sclerosis. This analysis aimed to update the previously reported serious treatment emergent adverse event (TEAE) profile of CT3.5 following integration of final data from the PREMIERE registry, and report post-approval safety data from worldwide sources.

The monotherapy oral cohort (CT3.5, N=923, patient-years [PY]=3936.69; placebo [PBO], N=641, PY=2421.47) was derived from the CLARITY, CLARITY Extension, and ORACLE-MS trials, and the PREMIERE registry. Adjusted incidences per 100PY were calculated for AEs, cumulative to the end of PREMIERE (October 2018). Serious and non-serious AEs from post-approval sources are also summarised.

Patient characteristics were balanced between treatment groups (mean age [37.8 years,CT3.5; 37.2 years,PBO], proportion of females [66.3%,CT3.5; 66.1%,PBO] and proportion of patients with prior disease modifying drug experience [19.9%,CT3.5; 20.4%,PBO]). Incidences per 100PY for ≥ 1 serious TEAE were 3.80 (CT3.5), and 3.05 (PBO). Incidences per 100PY for serious lymphopenia (preferred term [PT]) was 0.10 (CT3.5), 0 (PBO). For serious infections and infestations (system organ class), incidences per 100PY were 0.60 (CT3.5), 0.42 (PBO); for serious herpes zoster (PT): 0.05 (CT3.5), 0 (PBO). Incidences per 100PY for malignant tumours were 0.26 (CT 3.5), 0.12 (PBO). Post-approval sources reported 1622 AEs in the Periodic Benefit-Risk Evaluation Report, of which 275 were serious; none represented a new safety signal.

No new major safety findings were identified in this finalised integrated dataset which includes final data from PREMIERE. This profile is consistent with the previously published integrated safety analysis profile. No new safety signals were identified in the real world post-approval data of cladribine tablets.

doi: [10.1016/j.msard.2019.11.074](https://doi.org/10.1016/j.msard.2019.11.074)

Multiple Sclerosis and Related Disorders 37 (2020) 101600

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies

Gavin Giovanonni¹, Giancarlo Comi², Kottil Rammohan³, Peter Rieckmann⁴, Patrick Vermersch⁵, Fernando Dangond⁶, Birgit Keller⁷, Dominic Jack⁷

¹Queen Mary University of London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom

²Università Vita-Salute San Raffaele, Ospedale San Raffaele, Milan, Italy

³University of Miami School of Medicine, MS Research Center, Miami, United States

⁴United Arab Emirates

⁵Medical Park Loipl and University of Erlangen, Erlangen, Germany

⁶EMD Serono Research & Development Institute Inc., Billerica, United States

⁷Merck KGaA, Darmstadt, Germany

Treatment with cladribine tablets 10mg (cumulative dose 3.5mg/kg [CT3.5] over 2 years) in CLARITY and CLARITY Extension reduced relapse rate and slowed disability progression versus placebo in patients with relapsing remitting multiple sclerosis (RRMS). This post hoc analysis evaluated long-term disease stability assessed by the Expanded Disability Status Scale (EDSS) after treatment with CT3.5 in patients with RRMS in CLARITY and CLARITY Extension.

Patients randomised to CT3.5 in CLARITY and placebo in CLARITY Extension, with ≥ 1 post-baseline EDSS measurement, were included

(CP3.5; n=98). EDSS score over-time (from CLARITY randomisation to end of follow-up in CLARITY Extension, including the bridging interval between studies) was assessed at 6-monthly intervals, and separately time to 3- and 6-month confirmed EDSS score progression from CLARITY baseline. EDSS score worsening/improvement in each year was defined as any increase/decrease in minimum EDSS score at 6-monthly intervals; all other cases were classified as stable. Increase or decrease was defined as an EDSS score change of 1, 1.5 or 0.5 points at baseline EDSS ≤ 4.5 , 0, ≥ 5.0 respectively.

Five years post-CLARITY baseline, median EDSS remained stable versus baseline. Median EDSS score (95% confidence interval [CI]) for CP3.5 patients was 2.5(2.0-3.5) versus 3.0(2.5-3.5) at baseline. In each 12-month period, percentage of patients with EDSS score stability was $>50\%$; improvement, 21-30%; worsening, 0-25%. During Year 5, percentage of patients with EDSS stability was 53.9%; improvement, 21.3%; worsening, 24.7%. Less than 30% of patients reached 3- or 6-month confirmed EDSS progression by Year 5.

EDSS score was stable up to 5 years post-CLARITY baseline for the CP3.5 group. Between 20-30% of patients demonstrated improvement in EDSS score versus baseline each year.

doi: [10.1016/j.msard.2019.11.075](https://doi.org/10.1016/j.msard.2019.11.075)

Multiple Sclerosis and Related Disorders 37 (2020) 101601

Long Term, Registry-Based, Prospective, Post-Authorization Safety Study Evaluating Adverse Events of Special Interest in Patients with Highly Active Relapsing Multiple Sclerosis Newly Started on Cladribine Tablets – CLARION

Helmut Butzkueven¹, P. Korhonen², Jan Hillert³, M Trojano⁴, A. Aydemir⁵, Melinda Magyari⁶, H Khanfir², C Pinuaga⁷, Meritxell Sabido⁸

¹Central Clinical School, Monash University and The Alfred Hospital, Melbourne, Australia

²StatFinn and EPID Research (an IQVIA company), Espoo, Finland

³Karolinska Institute, Stockholm, Sweden

⁴University of Bari, Bari, Italy

⁵EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA), Billerica, United States

⁶Danish Multiple Sclerosis Center and The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

⁷Merck S.L.U, Madrid, Spain

⁸Merck KGaA, Darmstadt, Germany

To generate high quality safety data, multiple Sclerosis (MS) registries have begun to collect safety data more systematically, and use MedDRA coding of serious adverse events (SAE) to harmonise data collection across registries. Major MS registries and seven pharmaceutical companies all agreed on a common safety protocol, which is informing a standardised approach to the use of MS registries for SAE collection. CLARION is a prospective, multi-country, observational cohort study involving nine MS registries covering 14 countries. CLARION will evaluate the safety profile, in terms of adverse events of special interest (AESI), of patients initiating cladribine tablets (CT, n=4,000) versus those initiating fingolimod (n=4,000).

CLARION combines primary (Germany) and secondary data (other countries) and is projected to last up to 15 years with 10 years of follow-up for each included patient. Enrolled patients are those newly initiating CT or fingolimod according to the local label for MS after the date of CT launch in the relevant country or, in countries with primary data collection, after providing signed informed consent (<24 weeks after initiation of CT or fingolimod treatment). Patients are excluded if they received fingolimod prior to CT or if they received CT prior to fingolimod. Analysis of merged data from the different registries will be performed. Adjusted incidence rate and adjusted incidence rate ratios of each AESI